OakChart

Talphera Inc

TLPHHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 11:13 AM ET

1.07+0.02 (1.90%)
2026-11-11 17:16 CET
Market cap
54.50 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.08 USD m
Free cash flow, TTM
-12.27 USD m
EPS diluted, TTM
-0.26
P/E
-
Compare

Price

TLPH against its 20, 50 and 200-day averages
2050200beatearnings
0.801.001.201.40784K1.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TLPHclose 1.0720-day 1.0650-day 1.12200-day 1.011.07

31.8% under the 52-week high of 1.57 on 24 Nov 2025. 52-week low 0.69 on 6 Apr 2026. Last 15 sessions, 17.0% high to low

Profile

TLPH
52-week range, 43% of the way up
0.691.57

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes Nafamostat, LTX-608, and Niyad. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Employees12
IPOFeb 11, 2011
Beta0.73
ATR, 14d0.05
Rel volume0.97
Short float3.16%
Insider own25.69%
Inst own45.71%

Snapshot

6 groups

Valuation

Index-
Market Cap55.54M
Enterprise Value44.96M
Income-15.08M
Sales0.00M
Book/sh0.28
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPOFeb 11, 2011

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.86
P/C3.25
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.29
Current Ratio4.29
Debt/Eq0.45
LT Debt/Eq0.45
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.26
EPS next Y-0.21
EPS next Q-0.05
EPS this Y41.18%
EPS next Y-5.00%
EPS next 5Y28.04%
EPS past 3/5Y- 48.69%
Sales past 3/5Y- -65.11%
EPS Y/Y TTM35.57%
Sales Y/Y TTM-96.30%
EPS Q/Q43.47%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.4.00% -

Ownership

Insider Own25.69%
Insider Trans0.00%
Inst Own45.71%
Inst Trans0.53%
ROA-69.60%
ROE-143.36%
ROIC-72.12%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.85%
SMA50-4.41%
SMA2005.61%
Trades-

Technical

Shs Outstand51.91M
Shs Float38.57M
Short Float3.16%
Short Ratio7.17
Short Interest1.22M
52W High1.57 -31.85%
52W Low0.69 55.84%
Volatility7.56% 4.81%
ATR (14)0.05
RSI (14)48.91
Beta0.73
Rel Volume0.97
Avg Volume170.01K
Volume50,945

Performance

Perf Week1.90%
Perf Month0.00%
Perf Quarter-11.57%
Perf Half Y18.72%
Perf YTD-6.14%
Perf Year-17.05%
Perf 3Y131.10%
Perf 5Y-93.28%
Perf 10Y-98.35%
Recom1.00
Target Price3.12
Prev Close1.05
Price1.07
Change %1.90%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 05, 2026ResumedHH.C. WainwrightBuy$3+180.4%
Jan 28, 2025InitiatedRRodman & RenshawBuy$4+273.8%
Jul 20, 2020DowngradeCCredit SuisseNeutral → Underperform
Nov 11, 2019DowngradeCCredit SuisseOutperform → Neutral$7 → $2+86.9%
Aug 05, 2019ResumedCCredit SuisseOutperform
Jul 10, 2019ResumedCCredit SuisseOutperform
Apr 24, 2019ResumedBB. Riley FBRBuy$6.50+507.5%
Feb 15, 2019InitiatedCCredit SuisseOutperform$7+554.2%
Oct 23, 2018InitiatedBB. Riley FBRBuy$9+741.1%
Oct 13, 2017ReiteratedRRBC Capital MktsOutperform$6 → $5+367.3%

Peers

Mkt cap
TickerCompanyMkt cap
CPIXCumberland Pharmaceuticals Inc93.59M
AMPHAmphastar Pharmaceuticals Inc1.23B
RMTIRockwell Medical Inc28.29M
CRMDCorMedix Inc413.88M
HRTXHeron Therapeutics Inc66.23M
PCRXPacira BioSciences Inc1.46B
OMOutset Medical Inc80.49M
BAXBaxter International Inc13.57B
NEPHNephros Inc35.27M
ICUIICU Medical Inc4.48B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Angotti Vincent J.CHIEF EXECUTIVE OFFICERMar 13 '26Buy0.59213,310125,000800,705Mar 25 07:57 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERFeb 12 '26Buy0.81105,36485,587586,954Feb 20 08:28 PM
Aslam ShakilChief Medical OfficerFeb 12 '26Buy0.8135,00028,43083,178Feb 20 08:27 PM
Dasu Badri NChief Engineering OfficerFeb 12 '26Buy0.8135,00028,43076,230Feb 20 08:25 PM
ASADORIAN RAFFIChief Financial OfficerFeb 12 '26Buy0.8145,00036,55491,256Feb 20 08:23 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 206
  • Talphera's Q3 Report Is Really About Finishing Enrollment Before The Cash Runs Thin (Earnings Whispers)
  • Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 (PR Newswire)
  • Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ... (GuruFocus.com) -13.57%
  • Talphera: Q2 Earnings Snapshot (Associated Press)
  • Loading…
  • Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026 (PR Newswire) +5.93%
  • Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ... (GuruFocus.com)
  • Talphera: Q1 Earnings Snapshot (Associated Press) +5.11%
  • Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026 (PR Newswire)
  • Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 (PR Newswire) +9.08%
  • Talphera: Q4 Earnings Snapshot (Associated Press Finance)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.050--0.004
2026Q22026-08-12-0.060-0.063-0.0600.000.004
2026Q12026-05-13-0.040-0.067-0.0370.000.003
2025Q42026-03-23-0.060-0.075-0.0560.000.002
2025Q32025-11-12-0.110-0.125-0.1070.000.002
2025Q22025-08-14-0.100-0.130-0.1010.000.001
2025Q12025-05-14-0.100-0.143-0.0990.030.003
2024Q42025-03-31-0.070-0.165-0.0710.000.002
2024Q32024-11-13-0.130-0.190-0.1280.000.002
2024Q22024-08-14-0.150-0.213-0.1460.000.003
2024Q12024-05-14-0.160-0.250-0.1600.000.002
2023Q42024-03-06-0.250-0.200-0.2460.280.282
2023Q32023-11-08-0.080-0.280-0.0810.120.262
2023Q22023-08-10-0.410-0.530-0.4000.300.081
2023Q12023-05-10-0.750-0.785-0.7480.001.652
2022Q42023-03-30-1.000-0.510-1.0020.254.502

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-13.400-13.784-13.4472.292.81
2020FY-9.400-9.550-9.4725.426.20
2021FY-5.800-5.800-5.8572.824.66
2022FY5.7206.9505.7171.776.01
2023FY-1.290-1.235-1.2900.650.51
2024FY-0.500-0.590-0.5030.000.00
2025FY-0.340-0.355-0.3400.030.03
2026FY--0.200--0.00
2027FY--0.210--0.60
2028FY--0.127--13.73
2029FY-0.060--37.10
2030FY-0.243--65.23

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-222000.000.000.00
2026Q3S2026-08-133000.000.000.00
2026Q3S2026-08-123000.000.000.00
2026Q3S2026-06-033000.000.000.00
2026Q3S2026-05-142000.000.000.00
2026Q3S2026-04-291000.000.000.00
2026Q3R2026-10-27400-0.05-0.06-0.04
2026Q3R2026-08-13440-0.05-0.06-0.04
2026Q3R2026-08-12400-0.07-0.07-0.06
2026Q3R2026-07-28400-0.07-0.07-0.06
2026Q3R2026-06-03410-0.07-0.07-0.06
2026Q3R2026-05-14310-0.07-0.07-0.06
2026Q3R2026-04-29301-0.07-0.09-0.06
2026Q3R2026-03-23201-0.08-0.09-0.07

Estimate history

EPS, annual-22-16.145-13.447-9.472-5.8575.717-1.29-0.503-0.337-0.257
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.146-0.128-0.071-0.099-0.101-0.107-0.056-0.037-0.057
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual7.9952.1512.2895.4162.81800.65100.0280
Period201720182019202020212022202320242025TTM
Sales, quarterly0000.02700.001000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.5453.9383.9794.9416.8418.24416.95317.02949.32851.906
Period201720182019202020212022202320242025MRQ
Shares, quarterly16.99317.02617.02917.09820.52345.58649.32850.0551.906
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.030.000.650.002.825.422.292.15
Cost of Goods Sold Incl. D&A--0.000.311.653.756.036.813.98
Gross Profit--0.000.34-1.65-0.94-0.62-4.52-1.82
Selling, General and Administrative Excl. Other14.7513.5115.2517.2318.7035.5539.8549.6933.90
Research and Development6.706.036.725.241.694.094.024.6613.14
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.75-13.48-15.25-16.89-20.35-36.49-40.46-54.20-35.73
Interest Expense--0.390.131.122.293.312.5412.56
Unusual Expense0.951.31-1.960.00-79.10-0.360.690.12-0.09
Net Income Before Taxes-15.08-14.36-13.00-10.2959.14-35.09-40.38-53.24-47.15
Income Taxes0.000.000.000.000.010.010.000.000.00
Consolidated Net Income-15.08-14.36-13.00-10.2953.88-35.10-40.38-53.24-47.15
Net Income From Continuing Operations-15.08-14.36-13.00-10.2953.88-35.10-40.38-53.24-47.15
Net Income-15.08-14.29-13.00-18.4042.33-35.10-40.38-53.24-47.15
EPS (Recurring)-0.19-0.32-0.56-1.29-1.76-5.90-9.36-13.43-16.17
EPS (Basic, Before Extraordinaries)-0.26-0.34-0.50-1.295.73-5.86-9.47-13.45-16.14
EPS (Diluted)-0.26-0.34-0.50-1.295.72-5.86-9.47-13.45-16.14
EBITDA-14.75-13.48-15.25-16.58-18.70-34.51-38.61-52.54-35.15
Non-Operating Income (Expense)0.620.440.686.741.503.334.083.621.05
Other After Tax Adjustments0.000.000.000.00-5.240.000.000.000.00
Stock Option Compensation Expense0.790.700.991.732.283.363.233.694.08
Price To Earnings Ratio----0.36----
Price To Sales Ratio77,792.711,726.72-16.109.4523.8319.5272.9962.73
Gross Margin---52.23--33.18-11.37-197.34-84.84
Operating Margin--48,157.14--2,594.32--1,294.78-747.10-2,368.06-1,660.95
Net Margin--51,035.71--2,825.96--1,245.53-745.55-2,325.91-2,191.96
Shares Outstanding51.9149.3317.0316.958.246.844.943.983.94
Market Capitalization54.5054.508.9312.4616.8476.65122.53167.90181.93

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.030.000.00
Cost of Goods Sold Incl. D&A0.000.000.00-0.00-0.000.00
Gross Profit0.000.000.00-0.00-0.000.00
Selling, General and Administrative Excl. Other3.923.953.453.423.692.943.003.75
Research and Development1.691.651.561.801.501.171.322.05
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.92-3.95-3.45-3.42-3.69-2.92-3.00-3.75
Unusual Expense0.56-1.220.521.09-0.12-0.18-1.02-0.24
Net Income Before Taxes-4.31-2.56-3.77-4.44-3.49-2.67-1.87-3.35
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.31-2.56-3.77-4.44-3.49-2.67-1.87-3.35
Net Income From Continuing Operations-4.31-2.56-3.77-4.44-3.49-2.67-1.87-3.35
Net Income-4.31-2.56-3.77-4.44-3.49-2.59-1.87-3.35
EPS (Recurring)-0.05-0.05-0.05-0.09-0.10-0.10-0.10-0.13
EPS (Basic, Before Extraordinaries)-0.06-0.04-0.06-0.11-0.10-0.10-0.07-0.13
EPS (Diluted)-0.06-0.04-0.06-0.11-0.10-0.10-0.07-0.13
EBITDA-3.92-3.95-3.45-3.42-3.69-2.92-3.00-3.75
Non-Operating Income (Expense)0.170.170.200.080.080.070.100.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.240.210.180.150.170.200.230.23
Price To Sales Ratio77,792.7152,149.752,725.981,322.36588.55481.58-79.91
Operating Margin----342,200.00--10,800.00--
Net Margin----443,600.00--9,603.70--
Shares Outstanding51.9150.0549.3345.5920.5217.1017.0317.03
Market Capitalization54.5037.3853.1340.729.448.438.9314.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments20.388.869.3820.7751.6342.8966.14105.7260.47
Short Term Receivables0.000.000.000.000.160.730.600.401.53
Inventories0.000.000.000.001.111.633.290.850.96
Other Current Assets0.520.552.173.802.591.591.661.020.46
Total Current Assets20.909.4211.5624.5755.4946.8371.69107.9963.41
Net Property, Plant & Equipment0.000.000.000.0020.2318.8118.4811.4811.05
Total Investments and Advances0.000.000.000.000.000.000.000.180.18
Long-Term Note Receivable-----0.260.620.350.70
Other Assets8.828.828.8422.922.170.400.570.530.21
Total Assets29.7218.2420.3947.4977.8966.3091.36120.5375.55
Short Term Debt Incl. Current Port. of LT Debt0.000.000.005.369.869.965.959.008.33
Accounts Payable0.540.671.341.262.122.741.722.071.42
Other Current Liabilities3.271.983.187.156.524.945.944.863.90
Total Current Liabilities3.812.654.5113.7718.5117.6413.6115.9313.66
Long Term Debt6.500.000.000.0094.05104.11115.8496.6794.35
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.387.591.7811.901.230.303.323.694.05
Total Liabilities12.6810.236.2925.67113.79122.05132.77116.28112.06
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity17.048.0014.1121.81-35.89-55.75-41.424.25-36.51
Total Shareholders Equity17.048.0014.1121.81-35.89-55.75-41.424.25-36.51
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity17.048.0014.1121.81-35.89-55.75-41.424.25-36.51
Total Liabilities & Stockholders Equity29.7218.2420.3947.4977.8966.3091.36120.5375.55
Book Value Per Share0.350.470.832.65-5.25-11.28-10.411.08-14.35
Tangible Book Value Per Share0.350.470.832.65-5.25-11.28-10.411.08-14.35
Full-Time Employees121315194354996141
Price to Book Ratio3.780.930.680.61-2.14-2.20-4.0542.78-3.32
Return on Assets-59.90-67.32-30.3185.95-48.69-51.23-50.25-48.09-58.68
Return on Equity-114.74-117.65-57.28------
Return on Invested Capital-60.72-162.53-130.43194.90-60.36-83.49-71.54-46.72-89.05
Quick Ratio5.493.562.561.782.942.565.026.734.57
Current Ratio5.493.562.561.783.002.665.276.784.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-15.08-14.29-13.00-18.4042.33-35.10-40.38-53.24-47.15
Depreciation--0.000.311.651.971.851.670.57
Other Funds (Non Cash)1.371.840.552.13-70.922.922.314.3015.63
Funds from Operations-13.71-12.45-12.46-15.95-26.94-30.20-36.22-47.27-30.94
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.441.08-0.22-1.54-1.390.20-2.29-3.911.87
Cash from Operating Activities-12.27-11.36-12.68-17.49-28.33-30.00-38.51-51.18-29.07
Capital Expenditures0.000.000.00-0.10-0.36-2.65-1.85-3.47-0.82
Net Assets From Acquisitions0.000.000.000.00-1.690.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-15.96-14.353.78-3.1538.50-23.4835.99-33.09-10.06
Purchase of Investments-35.05-17.82-4.98-3.65-7.86-70.46-44.61-100.07-30.56
Sale Or Maturity of Investments19.103.478.760.5046.3646.9880.6166.9720.50
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.002.720.000.000.000.000.00
Cash from Investing Activities-15.96-14.353.78-0.5336.45-26.1234.14-36.56-10.88
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock22.1822.745.918.907.9850.6021.711.9882.74
Repurchase of Common Pref Stock0.010.000.000.00-0.320.000.000.000.00
Sale of Common Pref Stock22.1722.745.918.908.3050.6021.711.9882.74
Proceedsfrom Stock Options22.7122.725.888.867.9944.7221.341.2381.53
Issuance or Reduction of Debt, Net0.000.006.13-5.42-8.43-8.83-4.6712.48-7.72
Change in Long Term Debt0.000.006.13-5.42-8.43-8.83-4.6712.48-7.72
Issuance of Long Term Debt0.000.006.130.000.000.000.0025.00-
Reduction of Long Term Debt0.000.000.00-5.42-8.43-8.83-4.67-12.52-7.72
Net Financing Active Other Cash Flow0.000.000.00-0.02-0.06-0.25-0.090.000.00
Other Financing Activities Uses0.000.000.00-0.02-0.06-0.25-0.090.000.00
Cash from Financing Activities22.1822.7412.043.47-0.5141.5116.9614.4575.03
Net Change in Cash-6.05-2.973.14-14.557.61-14.6112.59-73.2935.07
Free Cash Flow-12.27-11.36-12.68-17.59-28.70-31.83-40.36-54.65-29.89
Preferred Dividends (Cash Flow)-0.000.000.00-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments17.0821.1120.3821.296.795.39
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.910.230.520.630.910.79
Total Current Assets17.9921.3420.9021.927.706.18
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets8.828.828.828.828.828.82
Total Assets26.8130.1629.7230.7416.5214.99
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.390.930.540.530.830.33
Other Current Liabilities3.803.103.272.691.791.66
Total Current Liabilities4.194.033.813.212.631.99
Long Term Debt6.506.506.506.506.506.53
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.711.152.381.850.760.88
Total Liabilities12.4011.6812.6811.569.899.40
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity14.4118.4817.0419.186.635.60
Total Shareholders Equity14.4118.4817.0419.186.635.60
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity14.4118.4817.0419.186.635.60
Total Liabilities & Stockholders Equity26.8130.1629.7230.7416.5214.99
Book Value Per Share0.280.370.350.420.320.33
Tangible Book Value Per Share0.280.370.350.420.320.33
Full-Time Employees--12---
Price to Book Ratio3.782.162.712.771.411.05
Return on Assets-69.60-63.14-59.90-48.15-55.00-53.54
Return on Equity-143.36-118.40-114.74-86.48-117.56-106.83
Return on Invested Capital-20.63-10.23-16.03-17.28-26.58-21.38
Quick Ratio4.295.305.496.832.933.11
Current Ratio4.295.305.496.832.933.11

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.31-2.56-3.77-4.44-3.49-2.59
Other Funds (Non Cash)0.65-1.090.581.230.020.01
Funds from Operations-3.66-3.65-3.19-3.21-3.47-2.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.260.250.750.700.52-0.89
Cash from Operating Activities-3.92-3.40-2.44-2.51-2.95-3.47
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments1.10-2.713.47-17.820.000.00
Purchase of Investments0.00-17.240.00-17.820.000.00
Sale Or Maturity of Investments1.1014.533.470.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.10-2.713.47-17.820.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.264.041.4016.994.35-0.01
Repurchase of Common Pref Stock0.000.000.000.01-0.00-0.01
Sale of Common Pref Stock-0.264.041.4016.984.350.00
Proceedsfrom Stock Options-4.054.041.3921.330.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.264.041.4016.994.35-0.01
Net Change in Cash-3.08-2.072.44-3.331.40-3.48
Free Cash Flow-3.92-3.40-2.44-2.51-2.95-3.47

Revenue breakdown

Total Pharmaceutical Preparations revenue2025: 28.00K
United States2025: 28.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.16%1.2M38.6M174.85K
2026-10-152.76%1.1M38.6M199.84K
2026-09-301.87%0.7M38.6M281.02K
2026-09-151.82%0.7M38.6M317.80K
2026-08-311.32%0.5M38.6M324.39K
2026-08-141.34%0.5M38.6M309.27K
2026-07-311.83%0.7M38.6M271.38K
2026-07-152.29%0.9M38.6M264.01K
2026-06-301.46%0.6M38.6M173.85K
2026-06-151.73%0.7M38.6M161.57K
2026-05-292.36%0.9M38.6M162.76K
2026-05-152.34%0.9M40.1M187.13K
2026-04-302.80%1.0M37.1M195.63K
2026-04-153.31%1.2M37.1M203.38K
2026-03-313.50%1.3M36.3M258.53K
2026-03-133.27%1.1M33.8M305.97K
2026-02-273.42%1.2M33.8M327.50K
2026-02-133.29%1.1M33.8M345.55K
2026-01-303.33%1.1M33.4M363.06K
2026-01-155.56%1.2M22.0M387.96K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.004.1290.000.000.173-0.0090.000
call5.000.000.750.006.2600.000.000.138-0.0130.000
call7.500.000.750.007.2750.000.000.127-0.0140.000
put2.501.051.800.009.3100.000.00-0.827-0.0100.000
put5.003.404.400.0013.1120.000.00-0.862-0.0120.000
put7.505.906.900.0014.4010.000.00-0.875-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-12SCHEDULE 13G/ASEC
2026-08-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-238-KCurrent report2026-06-22SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-12SCHEDULE 13G/ASEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-22SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-02SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-02SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-02SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-02SEC
2026-04-01EFFECTEffectiveness filing by commission orderSEC
2026-04-01424B7SEC
2026-03-30CORRESPSEC
2026-03-30UPLOADUpload SubmissionSEC
2026-03-254Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-03-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-2310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03125.00K100
2026-02179.00K400
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC13.46%
Rosalind Advisors, Inc.9.96%
AIGH Capital Management LLC8.26%
Rock Springs Capital Management LP6.92%
CANTOR FITZGERALD, L. P.3.42%
Bleichroeder LP2.52%
Dauntless Investment Group, LLC1.44%
VANGUARD CAPITAL MANAGEMENT LLC1.35%
Caption Management, LLC0.99%
Almitas Capital LLC0.90%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.85%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.50%
Fidelity Extended Market Index Fund0.41%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.07%

OakChart. TLPH. Cached 15 minutes.